The U.S. Food and Drug Administration has approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. Inflectra is

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In